Patents Assigned to Cadila Corporate Campus
  • Synthesis of novel intermediate(s) for preparing rivastigmine
    Patent number: 10882819
    Abstract: The present invention relates to novel intermediate(s), which are useful for the preparation of Rivastigmine compound of formula (I) and its pharmaceutically acceptable salts. The present invention further relates to the processes for the preparation of such novel intermediate(s) and preparation of Rivastigmine using such novel intermediate(s).
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: January 5, 2021
    Assignee: Cadila Corporate Campus
    Inventors: Jhillu Singh Yadav, Gyanchander Eppa, Pranav Rameshbhai Vachharajani, Nutan Bharatbhai Vekariya, Chetan Umeshbhai Bhavsar, Rajiv Indravadan Modi, Bakulesh Mafatlal Khamar
  • NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF
    Publication number: 20130137852
    Abstract: The present invention relates to process for preparation of novel compounds which are acting as inhibitors of dipeptidyl peptidase-IV enzyme and is depicted by the structural formula as given below: Formula VI. Which are useful in the treatment or prevention of diseases in which the dipeptidylpeptidase-IV enzyme is involved, such as diabetes and particularly type-2 diabetes.
    Type: Application
    Filed: August 3, 2011
    Publication date: May 30, 2013
    Applicant: Cadila Corporate Campus
    Inventors: Bakulesh Mafatlal Khamar, Nirav Kishorbhai Joshi, Chandan Hardhan Singh, Uday Rajaram Bapat, Bipin Dhanjibhai Gadhiya, Nirav Sureshbhai Sagar, Indravadan Ambalal Modi